

Triona Ni Chonghaile

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3851956/publications.pdf>

Version: 2024-02-01

41
papers

2,216
citations

471371

17
h-index

414303

32
g-index

41
all docs

41
docs citations

41
times ranked

4394
citing authors

#	ARTICLE	IF	CITATIONS
1	Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy. <i>Science</i> , 2011, 334, 1129-1133.	6.0	502
2	Bcl-2 family on guard at the ER. <i>American Journal of Physiology - Cell Physiology</i> , 2009, 296, C941-C953.	2.1	222
3	Mimicking the BH3 domain to kill cancer cells. <i>Oncogene</i> , 2008, 27, S149-S157.	2.6	218
4	Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. <i>Cancer Discovery</i> , 2014, 4, 1074-1087.	7.7	201
5	Mitochondria: gatekeepers of response to chemotherapy. <i>Trends in Cell Biology</i> , 2013, 23, 612-619.	3.6	140
6	BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. <i>Leukemia</i> , 2016, 30, 761-764.	3.3	128
7	MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. <i>Cell Reports</i> , 2015, 13, 2715-2727.	2.9	118
8	P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. <i>Blood</i> , 2012, 119, 1468-1478.	0.6	103
9	Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2017, 77, 3834-3845.	0.4	79
10	Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-XL. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 509-520.	1.6	78
11	Targeting the miR-221/222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. <i>Cancer Research</i> , 2015, 75, 4384-4397.	0.4	76
12	Cell and Molecular Determinants of <i>In Vivo</i> Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia Xenografts. <i>Clinical Cancer Research</i> , 2014, 20, 4520-4531.	3.2	67
13	The Emerging Role of Non-traditional Ubiquitination in Oncogenic Pathways. <i>Journal of Biological Chemistry</i> , 2017, 292, 3543-3551.	1.6	41
14	Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. <i>Science Advances</i> , 2021, 7, .	4.7	38
15	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 3094-3114.	4.2	37
16	Dexamethasone inhibits apoptosis in C6 glioma cells through increased expression of Bcl-XL. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2006, 11, 1247-1255.	2.2	29
17	BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7139-7150.	3.2	18
18	A Functional Genomic Screen Identifies the Deubiquitinase USP11 as a Novel Transcriptional Regulator of ER α in Breast Cancer. <i>Cancer Research</i> , 2020, 80, 5076-5088.	0.4	18

#	ARTICLE	IF	CITATIONS
19	The Anti-inflammatory Compound Candesartan Cilexetil Improves Neurological Outcomes in a Mouse Model of Neonatal Hypoxia. <i>Frontiers in Immunology</i> , 2019, 10, 1752.	2.2	16
20	Secondary plasma cell leukaemia treated with single agent venetoclax. <i>British Journal of Haematology</i> , 2020, 190, e242-e245.	1.2	12
21	Who Put the "in Atg12: Autophagy or Apoptosis?. <i>Molecular Cell</i> , 2011, 44, 844-845.	4.5	10
22	BCL-2 modulates the unfolded protein response by enhancing splicing of X-box binding protein-1. <i>Biochemical and Biophysical Research Communications</i> , 2015, 466, 40-45.	1.0	10
23	Advances in the Design and Development of PROTAC-mediated HDAC Degradation. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 408-424.	1.0	10
24	Shining a light on metabolic vulnerabilities in non-small cell lung cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188462.	3.3	9
25	The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL. <i>Blood Advances</i> , 2021, 5, 1963-1976.	2.5	9
26	Big Data"Led Cancer Research, Application, and Insights. <i>Cancer Research</i> , 2016, 76, 6167-6170.	0.4	7
27	JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1499-1507.	3.3	6
28	BH3 mimetics: Weapons of cancer cell destruction. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	5
29	Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 541-551.	1.5	4
30	Patient-derived organoids: Are PDOs the new PDX?. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	3
31	Ironing out dedifferentiation in melanoma. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	1
32	Venetoclax and Epigenetic Modifiers: Promising Novel Combinations for the Treatment of Multiple Myeloma. <i>Blood</i> , 2021, 138, 4703-4703.	0.6	1
33	Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index. <i>Blood</i> , 2011, 118, 1442-1442.	0.6	0
34	Therapeutic Targeting of the Bcl2 Family. <i>Blood</i> , 2013, 122, SCI-42-SCI-42.	0.6	0
35	BH3 Profiling Identifies Bcl-2 Dependency in Multiple Myeloma and Predicts Sensitivity to BH3 Mimetics. <i>Blood</i> , 2014, 124, 417-417.	0.6	0
36	Deadly role of chromosomal instability in metastasis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	0

#	ARTICLE	IF	CITATIONS
37	Fighting leukemia with "œduel"targeted therapy. Science Translational Medicine, 2018, 10, .	5.8	0
38	Identifying and targeting residual leukemic cells. Science Translational Medicine, 2018, 10, .	5.8	0
39	Illuminating Aurora dependencies. Science Translational Medicine, 2018, 10, .	5.8	0
40	The Splenic Microenvironment Is a Novel Site of Relapse Following ABT-199 Treatment. Blood, 2019, 134, 3800-3800.	0.6	0
41	Metabolic Changes in Venetoclax Resistance Are Determined By Differentiation State in T-Cell Acute Lymphoblastic Leukemia. Blood, 2021, 138, 3401-3401.	0.6	0